source
- Ned Sharpless joins Hatteras Venture Partners as managing director, Andrew Witty returns as chairmanHatteras Venture Partners, a North Carolina venture capital firm focused on life‑science startups, announced that former National Cancer Institute director Norman “Ned” Sharpless has joined the fir…
- Lilly's triple-agonist retatrutide drives up to 18.8% weight loss, over half of patients fall below obesity thresholdAt the EASD Annual Meeting in Milan, Eli Lilly presented data on its triple‑agonist retatrutide. The trial involved participants with obesity and type 2 diabetes and showed weight reductions of up…Endpoints · 21d agoPositive readoutPositive